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ABSTRACT 
The efficacy of health technologies, medicines and medical devices should be demonstrated in trails that evaluate final patient-relevant 
outcomes such as survival or morbidity. We provide a summary of the present use of surrogate end points in health care policy, discussing the 
case for and against their reviewing and adoption validation methods. Although the use of surrogates can be problematic, they can be validated 
and selected properly, offers important chances for more efficient clinical trials and faster access to new health technologies that benefit health 
care systems and patients. In early drug development studies, tumor response is often the true primary endpoint.  Usually clinical trials are 
needed to show that it can be dependent upon to predict, or correlate with, clinical benefit in a context of use. Surrogate endpoints that have 
undergone this ample testing are called validated surrogate endpoints and these are accepted by the Food and Drug Administration as evidence 
of benefit. Choosing the right surrogate endpoint and proving that it can predict the intended clinical benefit, however, is not always 
straightforward. When a disease has been sufficiently studied, surrogate endpoints can measure the underlying cause of a dise ase (such as low 
thyroxine levels and hypothyroidism) or an effect that predicts the ultimate outcome (such as measuring diuresis, which is expected to improve 
symptoms of heart failure).  
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Introduction: 
In the development of a pharmaceutical product, a clinical 
trial is the major part conducted for the demonstration of 
efficacy and safety of the product. The measurement used to 
assess the effect of the treatment is termed as endpoint. 
Endpoints used to measure clinical benefit, such as 
reduction of mortality rate and prolongation of survival 
time, are usually considered “true” endpoints because 
clinical benefits are the ultimate purpose of a medical 
treatment. However, the practicality and feasibility of 
measuring a “true” endpoint may be limited because of 
various reasons. Therefore, it is important to have some 
alternative measurement that would allow early assessment 
of a potential treatment effect. 
A surrogate endpoint is a biomarker that coordinates very 
well with the activity and toxicity of the molecule. It is 
generally an acceptable endpoint for registration of a 
molecule with regulatory agencies. A biomarker qualiﬁes as 
a surrogate endpoint for a clinical endpoint after controlled 
clinical trials which show a statistically and clinically 
signiﬁcant correlation between the two. Surrogate endpoints 
must reliably speculate both the safety and efficacy 
associated with a pharmacological agent. 
Surrogate endpoints are sometimes obtained from studies 
evaluating the natural history of the epidemiology. There are 
few examples of surrogate endpoint such as blood pressure 
is an accepted surrogate endpoint for anti-hypertensive 
agents as it predicts cardiovascular disease, heart failure, 
stroke and kidney failure [1]. For example, for several classes 
of agents bone mineral density has shown to have a good 
correlation with fracture rates. However, this has not turned 
out to be the case for fluoride [2]. 
The limitations of “true” endpoints prompted the use of 
surrogate endpoints. Surrogate endpoints that are 
considered to relate clinically important outcome but does 
not in itself measure a clinical benefit. 
This surrogate plays a particularly important role in the 
early development of a pharmaceutical product, when 
surrogate endpoints can be used to demonstrate if the drug 
has any pharmacological effect, as postulated by the in vitro 
model or in preclinical in vivo studies. 
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A surrogate is mainly useful if it is easily measured and 
highly correlated with the true endpoint. Often, 'true' 
endpoint is one with the clinical importance to the patient. 
For example, a major clinical outcome or mortality, while a 
surrogate is one biologically closer to the process of disease, 
for example, ejection fraction. Use of the surrogate can often 
lead to dramatic reductions in sample size and much shorter 
studies than use of the true endpoint [3] 
Atkinson [4] has compiled a table of biomarkers which have 
found varying degrees of clinical utility. Tables 1
 
Table 1: Biomarkers/surrogate endpoints that have aided drug development  
Biomarker / surrogate endpoint Type of drug Clinical endpoint 
Blood pressure Antihypertensive Agents Stroke, atherosclerosis. Heart failure 
Cholesterol LDL lowering statins Coronary artery disease, heart attacks 
Viral RNA Antiretroviral agents Survival, decrease in infections 
HbA1C, Glucose Antidiabetic agents Diabetic neuropathy 
CD4+ T cells Antiretroviral agents, cytokines Sustained reduction in viral RNA 
Intraocular pressure Antiglaucoma agents Preservation of peripheral vision 
Bone mineral density (BMD)  Antiosteoporotic agents Fracture rate 
MRI (Magnetic Resonance Imaging) Scans Agents for treatment of Multiple 
Sclerosis (MS) 
Decrease in rate of progression disease 
(check PDR) 
CT (Computed tomography) 
Scans for tumor size 
Anticancer agents Survival 
  
Surrogate Endpoint related to Oncology: 
Surrogate endpoint in oncology is widespread and 
increasing. The strength of association between the 
surrogates used and clinically meaningful outcomes is often 
weak or unknown. Attempts to validate surrogates are 
rarely undertaken. When this is done, validation relies on a 
fraction of available data, and often concludes that the 
surrogate is poor. Alternatively, if a drug fails to improve 
quality of life or overall survival, market authorization is 
rarely revoked [5] 
The most frequently used surrogates are response rate; a set 
of criteria distinguishing tumor shrinkage; and time to event 
endpoints, such as progression-free survival (PFS) or 
recurrence-free survival (RFS). Progression-free survival 
and Recurrence-free survival are composite endpoints 
where an event is explained as either growth of tumor 
beyond an arbitrary threshold (progression) or detectable 
recurrence of disease, or death. While there is debate as to 
whether PFS is intrinsically meaningful [6] since patients do 
not feel when they cross the arbitrary threshold of 
‘progression,’ we believe that PFS is, strictly speaking, a 
surrogate. 
Surrogate endpoint related to cardiovascular 
disease: 
A commonly used example in the cardiovascular disease is 
cholesterol. While elevated cholesterol levels increase the 
cause of heart disease, the relationship is not linear - many 
people with normal cholesterol develop heart disease, and 
many with high cholesterol do not. A clinical trial may show 
that a drug effective in reducing cholesterol, without 
showing directly that it prevents death. Proof of its 
efficaciousness in reducing cardiovascular disease was only 
presented five years after its original introduction, and then 
only for secondary prevention [7] 
Are surrogate endpoints important for medical 
product development? [8] 
When a surrogate endpoint clearly speculates a beneficial 
effect through appropriate studies, its use commonly allows 
for more efficient drug development programs. For example, 
many clinical trials, using a range of different blood pressure 
lowering medications, have demonstrated that reducing 
systolic blood pressure reduced the risk of stroke. Hence, 
quantification of reduction, surrogate endpoint of systolic 
blood pressure can stand in for the clinical outcome of 
stroke, and clinical trials targeting the reduction of risk of 
stroke that can be conducted more rapidly in smaller 
populations using this validated surrogate endpoint. 
 Why use a surrogate endpoint? 
 Faster and easier to study, 
        – e.g., Cholesterol or Blood Pressure vs. Stroke, Survival, 
Myocardial infarction. 
 Faster drug development, 
 Cheaper, 
 Proving effect on direct endpoint may not be 
practicable. 
         – Very low event rates – use of the surrogate in common 
clinical practice may make definitive trial seem unethical [9]. 
Examples of Surrogate Endpoints: [9] 
• Hypertension – arterial blood pressure: surrogate for 
Cerebrovascular accident, Myocardial Infarction, heart 
failure 
• Hypercholesterolemia –surrogate for atherosclerotic 
disease is basing on cholesterol levels. 
• Human Immunodeficiency Virus (HIV) – CD4 count or viral 
load: surrogate for complications of HIV 
• Glaucoma – surrogate for loss of vision is intraocular 
pressure. 
• Diabetes Mellitus – blood glucose / haemoglobin A1c: 
surrogate for complications. 
Limitations of using Surrogate endpoint: 
On yielding potentially important advantages, the use of 
surrogate endpoints, sometimes can show inappropriate 
results and thus causes problems. The two principal 
concerns on introduction of any proposed surrogate variable 
are it may not be true estimation of clinical outcome of 
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interest. For example, surrogate endpoint may measure the 
treatment activity associated with one of a specific 
pharmacological mechanism, but it may not provide exactly 
complete information on the range of actions and ultimate 
effects of the treatment whether it is positive or negative. 
There have been many examples where treatments showing 
a highly positive effect on a proposed surrogate have 
ultimately been shown to be detrimental to the subjects of 
clinical outcome; conversely, there are cases of treatments 
conferring clinical benefit without measurable effect on 
proposed surrogates [10]. Some of the cancer treatments 
provide a positive effect in a treatment in surrogate 
endpoint, but a detrimental effect on a patient health. In this 
case, although a treatment may achieve a certain degree of 
tumor shrinkage, the toxicity of the drug itself may in fact 
worsen a patient’s general health and thus shorten survival 
time. 
Regulatory Requirements: 
The Food and Drug Administration (FDA) must balance 
engaging needs in its approach to assess biomarkers, and it 
must do so with limited resources. On one hand, biomarkers 
are viewed as a route to reduce the cost and time required to 
develop effective new drugs, devices, and biologics to 
address chronic diseases; on the other hand, patients and 
consumers must be protected from risks associated with 
biomarker use. The perceptible efficiency dichotomy also 
applies to the use of biomarkers in health claims for foods, 
which the Food and Drug Administration regulates under a 
different framework than is applied to biologics, drugs and 
devices [11]. 
Validating a Surrogate Endpoint  
 For a surrogate to be useful, the relationship between 
the surrogate and the “direct” endpoint must be 
strongly established. Simple correlations, no matter 
how strong, are not enough. 
 The ideal method is the analyses of many studies of 
known effective drugs, which evaluated both the direct 
and surrogate endpoints, in order to establish (and 
quantitate) the relationship. 
 Very difficult to identify what type and quantity of data 
are sufficient to adequately validate a surrogate for use 
as a primary endpoint in a Phase 3 trial. 
 Once proved, a surrogate may be useful for future 
studies of medicines, particularly those with same 
mechanism of action. 
Conclusion: 
Post-marketing studies, planned to protect drugs have 
meaningful benefits, are often not performed. The potential 
for surrogate end points to have an impact on health care 
policy and the consequent diffusion of technologies into 
practice is illustrated by the fact that the primary outcome of 
more than 40% of pivotal trails used as the basis for 
approval of new indications is a surrogate that aims to 
substitute for and predict a final patient – relevant outcome.. 
The strength of association between the surrogates used and 
clinically meaningful outcomes are often unknown or weak. 
Attempts to validate surrogates are rarely undertaken. In 
both the cases surrogates must be used only when 
continuing studies examining hard endpoints have been fully 
enrolled. Relying on surrogates rather than final patient – 
relevant outcomes increases the uncertainty when making 
decisions about licensing and coverage of health care 
technologies. The use of appropriately validated surrogate 
end points, however, provides an unmissable opportunity to 
speed up access to innovative technologies that offer 
important benefits for patients and health care systems and 
to improve efficiency within the research and development 
environment. 
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